Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Background: This study describes a combination of between- and within patient in a two dimensional Response Surface
Pathway (RSP) design and introduce a randomization procedure in the clinical trial. This development is exemplified by a
dose-response study of Qlice in treatment of Atlantic salmon against sea lice (salmon louse).
Methods: The study was performed as a ?between-patient? three level RSP trial in single dose finding and ?within-patient?
RSP in duration of the dose. Reduction in lice was the outcome variable. The study consisted of 15 net pens (3.6 mill. salmon
incl. control) with minimum 4 lice/fish. The study was conducted to determine the minimum efficient dose (MED) of a new
treatment procedure. Adjustment of the dose from one design level to the next and duration between treatments within net
pens was based on k-adjustment factors estimated to ensure coverage of the entire two predefined windows. Three net pens
were included on the first dose/design level, five on the second and seven on the third. In order to obtain the ?between patient?
RSP in the dose arm, a randomization procedure was introduced.
Results: The optimal dose procedure of Qlice was estimated to 8.0 mg/kg biomass distributed during a period of 2 hours and
10 minutes. This dose procedure reduced the percent lice with 83.6%. No obvious interaction between dose and duration of
dosage was detected. No adverse events were recorded.
Conclusion: Both the two dimensional RSP design and the randomization procedure used in the dose-arm worked satisfactorily
in the field.
Biography
Trond Holand graduated as a veterinarian from the Norwegian School of Veterinary Science (NVH), Oslo, Norway in 1995. Besides experience from practice as
a veterinary surgeon, he is co-founder of US based OptiNose Inc. (www.optinose.com) with strong phase III results and has 12 years experience from medical
research and contributed to 8 publications in international medical journals. He started as a PhD fellow at NVH with Prof. Stig Larsen in 2013 and will finalize his
thesis in Clinical Research Methodology in 2015.
Relevant Topics
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals